- van Domburg RT, van Miltenburg-van Zijl AJ, Veerhoek RJ, Simoons ML. Unstable angina: good long-term outcome after a complicated early course. J Am Coll Cardiol 1998; 31: 1534-1539.
- Ellis SG. Percutaneous coronary intervention in the 1990s: results in patients with single or multivessel disease. Herz 1992; 17: 18-26.
- Myler RK, Shaw RE. Stertzer SH et al. Unstable angina and coronary angioplasty. Circulation 1990; 82 (suppl II): 88-95.
- de Feyter PJ, van den Brand MBJM, Laarman GJ et al. Acute coronary artery occlusion during and after percutaneous transluminal coronary angioplasty: frequency, prediction, clinical course, management, and follow-up. Circulation 1991; 83: 927-936.
- de Feyter PJ, Suryapranata H, Serruys PW et al. Coronary angioplasty for unstable angina: immediate and late results in 200 consecutive patients with identification for risk factors for unfavourable early and late outcome. J Am Coll Cardiol 1998; 12: 324-333.
- Lincoff AM, Popma JJ, Ellis SG, Hacker JA, Topol EJ. Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile. J Am Coll Cardiol 1992; 19: 926-935.
- Tenaglia AN, Fortin DF, Califf RM et al. Predicting the risk of abrupt vessel closure after angioplasty in an individual patient. J Am Coll Cardiol 1994; 24: 1004-1011.
- Abdelmeguid AE, Whitlow PL, Sapp SK, Ellis SG, Topol EJ. Long-term outcome of transient, uncomplicated in-laboratory coronary artery closure. Circulation 1995; 91: 2733-2741.
- de Feyter PJ, de Jaegere PP, Serruys PW. Incidence, predictors, and management of acute coronary occlusion after coronary angioplasty. Am Heart J 1994; 127: 643-651.
- The CAPTURE Investigators. Randomized placebo controlled trial of abciximab before and during intervention in refractory unstable angina: the CAPTURE study. Lancet 1997; 349: 1429-1435.
- Braunwald E, Maseri A, Armstrong PW et al. Rationale and clinical evidence for the use of GPIIb/IIIa inhibitors in acute coronary syndromes. Eur Heart J 1998; 19 (suppl D): D22-D30.
- The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-961.
- The EPILOG Investigators. Platelet IIb/IIIa receptor blockade and low dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689-1696.
- Hillegass WB. The economics of IIb/IIIa therapy. J Invas Cardiol 1996; 8 (suppl B): 30B-33B.
- van Hout BA, Simoons ML. Costs and effects of c7E3 in high risk PTCA patients: an indirect analysis for the Netherlands. Eur Heart J 1995; 16 (suppl I): 81-85.
- Chronos N, Vahanian A, Betriu A et al. Use of abciximab in interventional cardiology. Eur Heart J 1998; 19 (suppl D) D31-D39.
- Kereiakes DJ, Lincoff AM, Miller DP et al. Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes and bleeding complications. Circulation 1998; 97: 857-864.
- Umans VA, Kloeg PH, Bronzwaer J. The CAPTURE trial. Lancet 1997; 350: 445 (letter).
- Simoons ML, de Boer MJ, van den Brand MJ et al. Randomized trial of GPIIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation 1994; 89: 596-603.
- Kundu SK, Heilmann EJ, Sio R, Garcia C, Ostgaard RA. Characterization of an in vivo platelet function analyser: PFA-100. Clin Appl Thromb Hemost 1996; 2: 241-249.
- Tcheng JE. Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Am J Cardiol 1996; 78 (suppl 3A): 35-40.
- Topol EJ. Novel antithrombotic approaches to coronary artery disease. Am J Cardiol 1995; 75: 27B-33B.
- Lincoff AM, Califf RM, Anderson KM et al. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. J Am Coll Cardiol 1997; 30: 149-156.
- Théroux P, Kouz S, Roy L et al. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina: the Canadian Lamifiban Study. Circulation 1996; 94: 899-905.
- PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339: 436-443.
- Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1988; 338: 1498-1505.
- Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338: 1488-1497.
- The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998; 352: 87-92.
- Lincoff AM, Califf RM, Moliterno DJ et al. Complementary clinical benefit of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. N Engl J Med 1999; 341: 319-327.
- van Hout BA, Bowman L, Zelinger DJ, Simoons ML. Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk PTCA patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Am Heart J 1998; 135: S98-S106.
- Khan MM, Ellis SG, Aguirre FV et al. Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty? Clinical and angiographic outcomes in a large multicenter trial. J Am Coll Cardiol 1998; 31: 31-36.
- Hamm CW, Heeschen C, Goldman BU, Barnathan E, Simoons ML. Value of troponins in predicting therapeutic efficacy of abciximab in patients with unstable angina. J Am Coll Cardiol 1998; 31 (suppl A): 185A (abstr).
International Journal of Cardiovascular Interventions
Volume 2, 1999 - Issue 4